Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921010 · ClinicalTrials.gov registry record · Phase 4
Benefit of Elevation of HDL-C in Women
A Phase 4 study of Cardiovascular Outcomes, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT01921010 is a Phase 4 study of Cardiovascular Outcomes that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 43 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01921010, a Phase 4 study of Cardiovascular Outcomes, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction accomplished by the addition of niacin to statin medication would improve endothelial function as compared to LDL-C reduction alone in patients with and without coronary artery disease and the combination of low HDL-C/high triglycerides. The combination of lipid lowering therapy would have beneficial effects on markers of inflammation. These benefits would be particularly evident in women.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Niaspan
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2003-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01921010
The ClinicalTrials.gov registry entry for NCT01921010 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Outcomes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01921010 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01921010 about?
NCT01921010 is a clinical study titled "Benefit of Elevation of HDL-C in Women". The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction accomplished by the addition of niacin to statin medication would improve endothelial function as compared to LDL-C reduction alone in patients with and without coronary artery disease and the combination of lo...
What is the current status of trial NCT01921010?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2003-06. Estimated completion is 2005-06.
What conditions does trial NCT01921010 study?
This clinical trial studies the following conditions: Cardiovascular Outcomes.
What interventions are being tested in trial NCT01921010?
The interventions under investigation include: Placebo (DRUG), Niaspan (DRUG).
Who is sponsoring clinical trial NCT01921010?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01921010 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.